The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling

European Journal of Pharmaceutical Sciences

Volumn 38, Issue 5, 2009, Pages 512-518

  Vučićević, Katarina ^a   Miljković, Branislava ^a   Pokrajac, Milena ^a   Prostran, Milica ^a   Martinović, Žarko ^a   Grabnar, Iztok ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Interaction; NONMEM; Population pharmacokinetics; Therapeutic drug monitoring; Topiramate; Valproic acid

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; EFTIL; LAMOTRIGINE; LORAZEPAM; MIDAZOLAM; PHENOBARBITAL; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG ELIMINATION; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NONLINEAR SYSTEM; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NONLINEAR DYNAMICS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; VALPROIC ACID; YOUNG ADULT;

EID: 70449553615     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.09.017     Document Type: Article

References (41)

1. Ahn J.E., Birnbaum A.K., and Brundage R.C. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J. Pharmacokinet. Pharmacodyn. 32 (2005) 703-718
2. Anderson G.D., Acheampong A.A., Wilensky A.J., and Levy R.H. Effect of valproate dose on formation of hepatotoxic metabolites. Epilepsia 33 (1992) 736-742
3. Anderson G.D., Yau M.K., Gidal B.E., Harris S.J., Levy R.H., Lai A.A., Wolf K.B., Wargin W.A., and Dren A.T. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin. Pharmacol. Ther. 60 (1996) 145-156
4. Armijo J.A., Herranz J.L., Arteaga R., and Valiente R. Poor correlation between single-dose data and steady-state kinetics for phenobarbitone, primidone, carbamazepine and sodium valproate in children during monotherapy. Possible reasons for the lack of correlation. Clin. Pharmacokinet. 11 (1986) 323-335
5. Barett J.S. Population pharmacokinetics. In: Schoenwald R.D. (Ed). Pharmacokinetics in Drug Discovery and Development (2002), CRC Press, Boca Raton, FL 315-356
6. Bauer L.A. Applied Clinical Pharmacokinetics (2001), McGraw-Hill, New York pp. 516-549
7. Baxter K. Stockley's Drug Interactions (2006), Pharmaceutical Press, London
8. Beal S.L., Sheiner L.B., and Boeckmann A.J. NONMEM Users Guides (1989-2006), Icon Development Solutions, Ellicott City, Maryland, USA
9. Bialer M., Doose D.R., Murthy B., Curtin C., Wang S.S., Twyman R.E., and Schwabe S. Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet. 43 (2004) 763-780
10. Blanco-Serrano B., Garcia-Sanchez M.J., Otero M.J., Santos-Buelga D., Serrano J., and Dominguez-Gil A. Valproate population pharmacokinetics in children. J. Clin. Pharm. Ther. 24 (1999) 73-80
11. Blanco-Serrano B., Otero M.J., Santos-Buelga D., Garcia-Sanchez M.J., Serrano J., and Dominguez-Gil A. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm. Drug Dispos. 20 (1990) 233-240
12. Bondareva I.B., Jelliffe R.W., Sokolov A.V., and Tischenkova I.F. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implication for dosage. J. Clin. Pharm. Ther. 29 (2004) 105-120
13. Booth B.P., and Gobburu J.V.S. Considerations in anlysing single-trough concentrations using mixed-effects modeling. J. Clin. Pharmacol. 43 (2003) 1307-1315
14. Correa T., Rodriguez I., and Romano S. Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm. Drug Dispos. 29 (2008) 511-520
15. Drug Interaction Checker. Cerner Multum, Inc., Denver, CO. Available at: http://www.drugs.com/drug_interactions.html (accessed May 2008).
16. Eadie M.J. Therapeutic drug monitoring-antiepileptic drugs. Br. J. Clin. Pharmacol. 46 (1998) 185-193
17. El Desoky E.S., Fuseau E., El Din Amry S., and Cosson V. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur. J. Clin. Pharmacol. 59 (2004) 783-790
18. European Medicines Agency (EMEA), Committee for medicinal products for human use (CHMP), 2007. Guideline on reporting the results of population pharmacokinetic analyses. London.
19. Gidal B.E., and Garnett W.R. Epilepsy. In: DiPiro J.T., Talbert R.L., Yee G.C., Matzke G.R., Wells B.G., and Posey L.M. (Eds). Pharmacotherapy: A Pathophysiologic Approach (2005), McGraw-Hill, New York 1023-1048
20. Hooker A.C., Staatz C.E., and Karlsson M.O. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm. Res. 24 (2007) 2187-2197
21. Jiang D., and Wang L. Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy. Acta. Pharmacol. Sin. 25 (2004) 1576-1583
22. Jiang D., Wang L., Wang Y., Li L., Lu W., and Bai X. Population pharmacokinetics of valproate in Chinese children with epilepsy. Acta. Pharmacol. Sin. 28 (2007) 1677-1684
23. Legros B., Boon P., Dejonghe P., Sadzot B., van Rijckevorsel K., and Schmedding E. Opinion of Belgian neurologists on antiepileptic drugs: Belgian study on epilepsy treatment (BESET). Acta Neurol. Scand. 115 (2007) 97-103
24. Levy R.H., Shen D., Abbott F., Wayne Riggs K., and Hachad H. Valproic acid: chemistry, biotransformation, and pharmacokinetics. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippinocott Williams & Wilkins, Philadelphia, PA 780-800
25. Longin E., Teich M., Koelfen W., and König S. Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia 43 (2002) 451-454
26. Mataringa M.I., May T.W., and Rambeck B. Does lamotrigine influence valproate concentrations?. Ther. Drug Monit. 24 (2002) 631-636
27. McKee P.J.W., Percy-Robb I., and Brodie M.J. Therapeutic drug monitoring improves seizure control and reduces anticonvulsant side-effects in patients with refractory epilepsy. Seizure 1 (1992) 275-279
28. Murphy J.E. Clinical Pharmacokinetics Pocket Reference (2005), American Society of Health-System Pharmacists, Bethesda, MD
29. Park H.M., Kang S.S., Lee Y.B., Shin D.J., Kim O.N., Lee S.B., and Yim D.S. Population pharmacokinetics of intravenous valproic acid in Korean patients. J. Clin. Pharm. Ther. 27 (2002) 419-425
30. Patsalos P.N., and Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2 (2003) 347-356
31. Peterson G.M., and Naunton M. Valproate: a simple chemical with so much to offer. J. Clin. Pharm. Ther. 30 (2005) 417-421
32. Rosenfeld W.E., Liao S., Kramer L.D., Anderson G., Palmer M., Levy R.H., and Nayak R.K. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 38 (1997) 324-333
33. Schein J.R. Cigarette smoking and clinically significant drug interactions. Ann. Pharmacother. 29 (1995) 1139-1148
34. Seo K.W., Park M., Kim J.G., Kim T.W., and Kim H.J. Effect of benzothiazole on the xenobiotic metabolizizing enzymes and metabolism of acetaminophen. J. Appl. Toxicol. 20 (2000) 427-430
35. Sheiner L.B., and Beal S.L. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9 (1981) 503-512
36. Sheiner L.B., Rosenberg B., and Marathe V.V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharmacol. 5 (1977) 445-479
37. USP DI Volume I: Drug Information for the Health Care Professional, 2004, 24th ed. Thomson Micromedex, pp. 709-716, 2781-2786.
38. Vučićević K., Miljković B., Veličković R., Pokrajac M., Mrhar A., and Grabnar I. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. Ther. Drug Monit. 29 (2007) 781-788
39. Wade J.R., Kelman A.W., Howie C.A., and Whiting B. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J. Pharmacokinet. Biopharmacol. 21 (1993) 209-222
40. Yukawa E., Nonaka T., Yukawa M., Higuchi S., Kuroda T., and Goto Y. Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients. J. Clin. Pharm. Ther. 28 (2003) 497-504
41. Yukawa E., To H., Ohdo S., Higuchi S., and Aoyama T. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J. Clin. Pharmacol. 37 (1997) 1160-1167